Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits?

Area of Science:

• Infectious Diseases
• Clinical Microbiology
• Pharmacology

Background:

• Severe methicillin-resistant Staphylococcus aureus (MRSA) infections are often treated with vancomycin, despite evidence of poor outcomes and increasing resistance.
• Current vancomycin susceptibility breakpoints may not accurately reflect clinical efficacy, with evidence suggesting lower thresholds are clinically relevant.
• Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets with vancomycin for severe MRSA infections remains a challenge.

Purpose of the Study:

• To evaluate the current use of vancomycin for severe MRSA infections.
• To discuss the limitations of current vancomycin susceptibility testing and breakpoints.
• To suggest alternative treatment strategies and the need for further research.

Main Methods:

• Review of existing clinical evidence and pharmacokinetic/pharmacodynamic (PK/PD) data for vancomycin in MRSA infections.
• Analysis of current and proposed minimum inhibitory concentration (MIC) susceptibility breakpoints for vancomycin.
• Assessment of the performance and limitations of automated susceptibility testing systems.

Main Results:

• Accumulating evidence suggests vancomycin is associated with poor outcomes in severe MRSA infections.
• Current MIC susceptibility breakpoints (2 mg/L) may overestimate vancomycin susceptibility; method-dependent breakpoints (0.5–1.0 mg/L) are proposed.
• Automated testing systems struggle with accuracy at lower MIC levels, leading to critical reproducibility issues around 1 mg/L.

Conclusions:

• Vancomycin should be used with caution in severe staphylococcal disease, with MICs reported by method.
• Alternative agents like daptomycin (for bacteremia/endocarditis) and linezolid (for pneumonia) are generally preferred.
• Urgent need for better outcome data for vancomycin based on achievable PK/PD targets and robust MIC testing.